Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Metrics to compare | ORKA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipORKAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −17.0x | −7.5x | −0.7x | |
PEG Ratio | - | 0.35 | 0.00 | |
Price/Book | 3.9x | 9.5x | 2.6x | |
Price / LTM Sales | - | 101.8x | 3.4x | |
Upside (Analyst Target) | 60.5% | 97.3% | 38.2% | |
Fair Value Upside | Unlock | −15.2% | 4.6% | Unlock |